North Korea-Linked Hackers Steal $2.02 Billion in 2025, Leading Global Crypto Theft
Threat actors with ties to the Democratic People’s Republic of Korea (DPRK or North Korea) have been instrumental in driving a surge in global cryptocurrency theft in 2025, accounting for at least $2.02 billion out of more than $3.4 billion stolen from January through early December. The...
ThreatsDay Bulletin: WhatsApp Hijacks, MCP Leaks, AI Recon, React2Shell Exploit and 15 More Stories
This week’s ThreatsDay Bulletin tracks how attackers keep reshaping old tools and finding new angles in familiar systems. Small changes in tactics are stacking up fast, and each one hints at where the next big breach could come from. From shifting infrastructures to clever social hooks, the...
HPE OneView Flaw Rated CVSS 10.0 Allows Unauthenticated Remote Code Execution
Hewlett Packard Enterprise (HPE) has resolved a maximum-severity security flaw in OneView Software that, if successfully exploited, could result in remote code execution. The critical vulnerability, assigned the CVE identifier CVE-2025-37164, carries a CVSS score of 10.0. HPE OneView is an IT...
Antibodies to watch in 2026
Thursday 29 January 2026 07:00 10:00 15:00 In this webinar, presented in association with the journal mAbs, Drs. Crescioli and Reichert discuss recent trends in antibody therapeutics development and forecast key events that may occur in 2026. They will begin with a brief review of approvals...
Key Signs of Mental Health Struggles in Security
John Rodriguez, Founder of Empathic Security Cultures LLC, shares why mental health is so crucial in security. Continue reading →
No More Failures of Imagination: Future Proofing Airport Employee Screening
How to protect American flyers and airport employees from another tragic “failure of imagination.” Continue reading →
630M Passwords Stolen, FBI Reveals: What This Says About Credential Value
630 million passwords were stolen, highlighting the value of passwords and password protection. Continue reading →
Peanut allergy patch succeeds in late-stage study 5 years after FDA rejection
DBV Technologies plans to use the latest Phase 3 results in a new submission to U.S. regulators in 2026. Continue reading →
FDA clears GSK’s twice-yearly asthma drug
Exdensur is now the first asthma biologic to be approved for twice-yearly dosing, and could potentially change standard of care for those with severe disease. Continue reading →